During Wednesday’s Current trade, Shares of Air Products & Chemicals, Inc. (NYSE:APD), lost -0.86% to $144.77.
Air Products (APD) declared that Scott Crocco, senior vice president and chief financial officer, will present at the Jefferies 2015 Industrials Conference in New York on Tuesday, August 11, 2015 at 2:40 p.m. ET.
Air Products and Chemicals, Inc. provides atmospheric gases, process and specialty gases, performance materials, equipment, and services worldwide. The company operates in Merchant Gases, Tonnage Gases, Electronics and Performance Materials, and Equipment and Energy segments. The Merchant Gases segment sells atmospheric gases, such as oxygen, nitrogen, and argon; process gases, such as hydrogen, helium, and carbon dioxide; specialty gases; temporary gas supply services; and equipment for the metals, glass, electronics, chemical processing, food processing, healthcare, general manufacturing, and petroleum and natural gas industries.
Shares of STMicroelectronics NV (ADR) (NYSE:STM), declined -1.51% to $7.19, during its current trading session.
STMicroelectronics (STM), a global semiconductor leader serving customers across the spectrum of electronics applications, declared the STiD325 (codenamed Barcelona), its DOCSIS[1] 3.1 chipset for Broadband CPE[2] Cable Modems, embedded Media Terminal Adapters (eMTAs), and Gateways, in addition to for Video Gateways when associated to set-top-box chipsets. It is being demonstrated at CableLabs Summer Conference, August 2-5, 2015 in Keystone, Colorado, USA.
DOCSIS 3.1 has been engineered by CableLabs(R) to unleash the multi-gigabit data era on existing Hybrid Fiber-Coax (HFC) netoperates through improved spectral efficiency using OFDM[3] multi-carrier modulation combined with low-density parity-check-based Forward Error Correction.
STMicroelectronics N.V. designs, develops, manufactures, and markets various semiconductor integrated circuits and discrete devices worldwide. The company offers a range of semiconductor products, counting discrete and standard commodity components, application-specific integrated circuits, full-custom devices and semi-custom devices, micro-electro-mechanical systems, microcontrollers, sensors, digital consumer products, imaging products, memory products, media application processors, and application-specific standard products for analog, digital, and mixed-signal applications, in addition to silicon chips and smartcards.
OHR Pharmaceutical Inc (NASDAQ:OHRP), during its Wednesday’s current trading session decreased -2.30% to $2.55.
Ohr Pharmaceutical, Inc. (OHRP), stated results for its third fiscal quarter ended June 30, 2015.
Corporate Highlights for the Quarter Ended June 30, 2015, and Recent Events
- In April, presented detailed results on OHR-102 from the IMPACT study at the Association for Research in Vision and Ophthalmology (ARVO) meeting in Denver, Colorado
- Topically administered OHR-102 combination therapy led to improved visual function in patients with wet AMD.
- Patients with classic containing CNV demonstrated a mean gain in visual acuity at month nine of +11 letters for the OHR-102 combination arm and +5 letters with Lucentis(R) monotherapy, a clinically meaningful benefit of 6 letters. In addition, 44% of patients treated with OHR-102 combination therapy gained 3 or more lines of vision contrast to only 29% in the Lucentis monotherapy group at month 9.
- Patients with an occult CNV area less than 10mm2, regardless of classic CNV being present, treated with the combination of OHR-102 and Lucentis PRN, demonstrated a positive visual acuity benefit contrast to the Lucentis monotherapy arm which was similar to that seen in the classic containing CNV population.
- As formerly stated, the mean number of injections between the treatment arms, the primary endpoint of the study, was not meaningfully different.
OHR Pharmaceutical, Inc., a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is OHR-102 eye drops, a novel therapeutic product, which could provide a non-invasive therapy to improve vision outcomes.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
